Samjin Pharmaceutical Applies for Phase 1 IND for Immune and Inflammatory Drug Candidate "SJN314"
Non-clinical Studies Supported by the Korea Drug Development Fund
Samjin Pharmaceutical announced on the 4th that it has submitted an Investigational New Drug (IND) application to the Ministry of Food and Drug Safety for a Phase 1 clinical trial of its new immune and inflammatory disease treatment candidate, "SJN314".
Exterior view of the Samjin Pharmaceutical Research Center. Samjin Pharmaceutical
View original imageSJN314 is an oral small-molecule MRGPRX2 inhibitor being developed for inflammatory diseases such as chronic spontaneous urticaria and atopic dermatitis. The non-clinical studies were conducted with support from the Korea Drug Development Fund (KDDF).
MRGPRX2 is a receptor involved in mast cell activation via a non-IgE pathway. It is being investigated as a new therapeutic target for patient groups who do not respond to existing antihistamines or IgE-based therapies. Recently, global pharmaceutical companies have been actively pursuing clinical development and technology transfer for related pipelines.
This Phase 1 clinical trial will evaluate safety, pharmacokinetic characteristics, and tolerability in healthy adults. The trial will be conducted by the clinical pharmacology research team at Seoul National University Hospital and will include comparative assessments between Korean and Caucasian participants. Based on the human data obtained in the early clinical stage, Samjin Pharmaceutical plans to review subsequent clinical development and global partnering opportunities.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Lee Sumin, Head of the Research Center at Samjin Pharmaceutical, said, "We have entered the clinical stage based on the data accumulated through non-clinical studies," adding, "We will proceed with development with a view toward global technology transfer and co-development."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.